Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Neuronal pentraxin 1 (NP1)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Neuronal damage
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Neuronal pentraxin 1 (NP1) is a potential plasma biomarker of synaptic dysfunction. NP1 is increased in patients with MCI and mild AD dementia.

What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, United States; Veterans Affairs Greater Los Angeles Healthcare System, United States; Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; School of Nursing, University of California, Los Angeles, United States; Departments of Neurology, Radiology, and Medical and Molecular Genetics, Indiana University School of Medicine, United States; Department of Anatomy and Cell Biology, University of Illinois at Chicago, United States; The Johns Hopkins University School of Medicine, The Kennedy Krieger Institute, United States; Genentech, Inc. (a member of the Roche Group); The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal

  1. Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018). A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer's disease. PROTEOMICS–Clinical Applications, 12(1), 1700131. https://www.ncbi.nlm.nih.gov/pubmed/29028155

  2. Ma, Q. L., Teng, E., Zuo, X., Jones, M., Teter, B., Zhao, E. Y., ... & LaDu, M. J. (2018). Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease. Neurobiology of Disease, 114, 120-128. https://www.ncbi.nlm.nih.gov/pubmed/29501530

  3. Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D., Zhu, Y., Haznedar, J., ... & Honigberg, L. A. (2014). Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics. Molecular neurodegeneration, 9(1), 22. https://www.ncbi.nlm.nih.gov/pubmed/24902845